Baltimore, MD – According to filings with the U.S. Securities and Exchange Commission, AsclepiX Therapeutics is raising $35,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Kevin Slawin played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About AsclepiX Therapeutics

AsclepiX Therapeutics is focused on transforming the treatment of ocular diseases and cancer through the rapid clinical development of groundbreaking therapies aimed at empowering patients and their families around the world with the freedom to live their best lives. Using pioneering computational biology methods, we have identified multiple families of peptides that are potent regulators of vascular homeostasis. Our clinical candidates are derived from these peptides and work through naturally existing, highly evolved, and self regulating mechanisms of homeostasis that maintain our health and well being.

To learn more about AsclepiX Therapeutics, visit http://www.asclepix.com/

Contact:
Kevin Slawin, Chief Executive Officer
610-212-1217
kslawin@asclepix.com
https://www.linkedin.com/in/kevinslawin/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved